|

NBI-1065845 Clinical Trials

5 actively recruiting trials across 4 locations

Also known as: TAK-653

Pipeline

Phase 3: 5

Top Sponsors

  • Neurocrine Biosciences5

Indications

  • Major Depressive Disorder5
  • Depression5

Little Rock, Arkansas2 trials

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Neurocrine Clinical Site

Phase 3
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Neurocrine Clinical Site

Phase 3

Huntsville, Alabama1 trial

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Neurocrine Clinical Site

Phase 3

Los Angeles, California1 trial

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Neurocrine Clinical Site

Phase 3

Oceanside, California1 trial

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Neurocrine Clinical Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.